Europe Overactive Bladder Treatment Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028

Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)   

No. of Pages: 153
Report Code: BMIRE00027805
Category: Life Sciences
Europe Overactive Bladder Treatment Market

The Europe overactive bladder treatment market is expected to grow from US$ 1,111.05 million in 2022 to US$ 1,318.55 million by 2028; it is estimated to grow at a CAGR of 2.9% from 2022 to 2028.

 

Growing Incidence of Urinary Tract Infections Fuels Europe Overactive Bladder Treatment Market Growth

 

Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities can further damage the integrity of the urothelial barrier. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Moreover, as per the National Institute for Health and Care Excellence organization, UTIs are among the most common hospital-acquired infections in the UK, accounting for ~23% of all infections. According to the BMC Family Practice, UTI consultations accounted for ~2% of ED visits in the Netherlands in 2019. Similarly, in France, ~4–6 million people suffer from UTI each year. Thus, the increasing incidence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the Europe overactive bladder treatment market growth.    

 

Europe Overactive Bladder Treatment Market Overview

 

The Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global overactive bladder treatment market and is estimated to register a substantial CAGR over the forecast period. The growing demand for overactive bladder treatment due to the presence of the geriatric population is driving the market growth in Europe. Further, the prevalence of neurological diseases and diabetes hampering urinary tract functions is likely to create opportunities for the growth of overactive bladder treatment in the coming years. According to the UK Parliament’s data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Besides, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. Diabetes UK states that ~3.9 million people were diagnosed with diabetes in 2019, and it reached 4.7 million in 2021. The rising prevalence of diabetes and the growing elderly population in the UK lead to surging cases of overactive bladder condition, thereby stroking the demand for its treatment.

 

Europe Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million) 

Europe Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)                

 

Europe Overactive Bladder Treatment Market Segmentation

 

The Europe overactive bladder treatment market is segmented into pharmacotherapy, disease type, and country.

 

The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

  • Based on pharmacotherapy, the market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.
  • Based on disease type, the Europe overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.
  • Based on country, the Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the market in 2022.  

AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the overactive bladder treatment market in Europe.    

Europe Overactive Bladder Treatment Market Strategic Insights

global-market-strategic-framework
Get more information on this report

Europe Overactive Bladder Treatment Market Segmentation Analysis

Europe Overactive Bladder Treatment Market Report Highlights

Europe Overactive Bladder Treatment Report Scope

Report Attribute Details
Market size in 2022 US$ 1,111.05 Million
Market Size by 2028 US$ 1,318.55 Million
CAGR (2022 - 2028) 2.9%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By Pharmacotherapy
  • Anticholinergics
  • Mirabegron
  • Botox
  • Neurostimulation
  • Intravesical Instillation
By Disease Type
  • Idiopathic Overactive Bladder and Neurogenic Bladder
Regions and Countries Covered
Europe UK, Germany, France, Russia, Italy, Rest of Europe
Market leaders and key company profiles
  • AbbVie Inc
  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc
  • Endo Pharmaceuticals Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Medtronic Plc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
Get more information on this report

Europe Overactive Bladder Treatment Market Country and Regional Insights

europe-overactive-bladder-treatment-market
Get more information on this report
The List of Companies - Europe Overactive Bladder Treatment Market
  1. AbbVie Inc
  2. Alembic Pharmaceuticals Limited
  3. Astellas Pharma Inc
  4. Endo Pharmaceuticals Inc.
  5. Hisamitsu Pharmaceutical Co., Inc.
  6. Medtronic Plc
  7. Pfizer Inc
  8. Teva Pharmaceutical Industries Ltd
Frequently Asked Questions
How big is the Europe Overactive Bladder Treatment Market?

The Europe Overactive Bladder Treatment Market is valued at US$ 1,111.05 Million in 2022, it is projected to reach US$ 1,318.55 Million by 2028.

What is the CAGR for Europe Overactive Bladder Treatment Market by (2022 - 2028)?

As per our report Europe Overactive Bladder Treatment Market, the market size is valued at US$ 1,111.05 Million in 2022, projecting it to reach US$ 1,318.55 Million by 2028. This translates to a CAGR of approximately 2.9% during the forecast period.

What segments are covered in this report?

The Europe Overactive Bladder Treatment Market report typically cover these key segments-

  • Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, Intravesical Instillation)
  • Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)

What is the historic period, base year, and forecast period taken for Europe Overactive Bladder Treatment Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Overactive Bladder Treatment Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Europe Overactive Bladder Treatment Market?

    The Europe Overactive Bladder Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • AbbVie Inc
  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc
  • Endo Pharmaceuticals Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Medtronic Plc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
  • Who should buy this report?

    The Europe Overactive Bladder Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Overactive Bladder Treatment Market value chain can benefit from the information contained in a comprehensive market report.

    Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Sales Assistance
    +1 646 791 7070 (US & UK)
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)